Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Change in Cash (2016 - 2025)

Xtant Medical Holdings (XTNT) has disclosed Change in Cash for 16 consecutive years, with $3.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Cash rose 124.13% to $3.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.6 million, a 313.77% increase, with the full-year FY2024 number at $298000.0, up 102.04% from a year prior.
  • Change in Cash was $3.6 million for Q3 2025 at Xtant Medical Holdings, up from $1.6 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $16.3 million in Q1 2021 to a low of -$15.1 million in Q1 2023.
  • A 5-year average of $436842.1 and a median of -$124000.0 in 2022 define the central range for Change in Cash.
  • Peak YoY movement for Change in Cash: surged 1379.3% in 2022, then plummeted 966.17% in 2023.
  • Xtant Medical Holdings' Change in Cash stood at -$227000.0 in 2021, then soared by 1379.3% to $2.9 million in 2022, then plummeted by 197.31% to -$2.8 million in 2023, then soared by 69.39% to -$865000.0 in 2024, then skyrocketed by 516.65% to $3.6 million in 2025.
  • Per Business Quant, the three most recent readings for XTNT's Change in Cash are $3.6 million (Q3 2025), $1.6 million (Q2 2025), and -$786000.0 (Q1 2025).